Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9262114 | 0.98 | LMNA (0.46) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8459302 | 0.98 | LMNA (0.46) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL78111 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHRCA2 | |
| SCHEMBL9425652 | 0.91 | LMNA (0.46) | LMNAGPR84FFAR1MAPTOPRM1 | |
| SCHEMBL27538738 | 0.88 | LMNA (0.50) | LMNAGPR84FFAR1MAPT | |
| SCHEMBL16196233 | 0.88 | LMNA (0.50) | LMNAGPR84FFAR1MAPT | |
| SCHEMBL5274110 | 0.86 | LMNA (0.43) | LMNAGPR84FFAR1MAPTOPRM1 | |
| SCHEMBL8705110 | 0.84 | LMNA (0.46) | LMNAGPR84FFAR1MAPT | |
| SCHEMBL9263682 | 0.84 | LMNA (0.46) | LMNAGPR84FFAR1MAPT | |
| SCHEMBL2870649 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| US-20140350269-A1 | Acetals Esters Produced from Purified Glycerin for Use and Application as Emollients, Lubricants, Plasticizers, Solvents, Coalescents, Humectant, Polymerization Monomers, Additives to Biofuels | GLYCEROSOLUTION QUÍMICA LTDA. (BR) | 2014-11-27 | — | — | US | claimed |
| EP-2799433-A2 | Acetals esters produced from purified glycerin for use and application as emollients, lubricants, plasticizers, solvents, coalescents, humectant, polymerization monomers, additives to biofuels | Glycerosolution Quimica, Ltda (BR) | 2014-11-05 | — | — | EP | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11939421-B2 | Or relating to curing agents | HEXCEL COMPOSITES LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| US-11879052-B2 | Curatives | HEXCEL COMPOSITES LIMITED (GB) | 2024-01-23 | — | — | US | disclosed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4379780-A | 17 α-Dihydroequilin hapten and assay method | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| US-4379779-A | Equilin hapten and assay method | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350269-A1 | Acetals Esters Produced from Purified Glycerin for Use and Application as Emollients, Lubricants, Plasticizers, Solvents, Coalescents, Humectant, Polymerization Monomers, Additives to Biofuels | GK, DAGLA, DAGLB | ALDH1A1 731/4885TDP1 452/4885LMNA 1568/4885 |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | UPF1, RBM17, NSUN2 | ALDH1A1 3895/4885TDP1 328/4885LMNA 385/4885 |
| US-11939421-B2 | Or relating to curing agents | FABP4, RARA, ADIPOR1 | ALDH1A1 131/4885TDP1 1408/4885LMNA 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.